tbuckley/cabot-search huggingface dataset:
STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs
Authors: Barbara Walch-Rückheim, Jennifer Pahne-Zeppenfeld, Jil Fischbach, Claudia Wickenhauser, Lars Christian Horn, Lars Tharun, Reinhard Büttner, Peter Mallmann, Peter Stern, Yoo-Jin Kim, Rainer Maria Bohle, Christian Rübe, Russalina Ströder, Ingolf Juhasz-Böss, Erich-Franz Solomayer, Sigrun Smola
Journal: Cancer Research (2016)

Abstract Neoadjuvant radio/chemotherapy regimens can markedly improve cervical cancer outcome in a subset of patients, while other patients show poor responses, but may encounter severe adverse effects. Thus, there is a strong need for predictive biomarkers to improve clinical management of cervical cancer patients. STAT3 is considered as a critical antiapoptotic factor in various malignancies. We therefore investigated STAT3 activation during cervical carcinogenesis and its impact on the response of cervical cancer cells to chemotherapeutic drugs. Tyr705-phosphorylated STAT3 increased from low-grade cervical intraepithelial neoplasia (CIN1) to precancerous CIN3 lesions. Notably, pTyr705-STAT3 activation significantly declined from CIN3 to invasive cancer, also when compared in the same clinical biopsy. pTyr705-STAT3 was also low or absent in cultured human cervical cancer cell lines, consistent with the in vivo expression data. Unexpectedly, IL6-type cytokine signaling inducing STAT3 activation rendered cervical cancer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide. This chemosensitization was STAT3-dependent and we identified IFN regulatory factor-1 (IRF1) as the STAT3-inducible mediator required for cell death enhancement. In line with these data, pTyr705-STAT3 significantly correlated with nuclear IRF1 expression in cervical cancer in vivo. Importantly, high IRF1 expression in pretreatment cervical cancer biopsy cells was associated with a significantly better response to neoadjuvant radio/chemotherapy of the patients. In summary, our study has identified a key role of the STAT3/IRF1 pathway for chemosensitization in cervical cancer. Our results suggest that pretherapeutic IRF1 expression should be evaluated as a novel predictive biomarker for neoadjuvant radio/chemotherapy responses. Cancer Res; 76(13); 3872–83. ©2016 AACR.
Reticulostimulating Properties of Killed Vaccines of Anaerobic Coryneforms and Other Organisms 2
Authors: C. S. Cummins, D. M. Linn
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Reticulostimulating Properties of Killed Vaccines of Anaerobic Coryneforms and Other Organisms Get access C. S. Cummins, C. S. Cummins 3Anaerobe Laboratory, Virginia Polytechnic Institute and State University,, Blacksburg, Va. 24061 Search for other works by this author on: Oxford Academic PubMed Google Scholar D. M. Linn D. M. Linn 3Anaerobe Laboratory, Virginia Polytechnic Institute and State University,, Blacksburg, Va. 24061 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 6, December 1977, Pages 1697–1708, https://doi.org/10.1093/jnci/59.6.1697 Published: 01 December 1977 Article history Received: 01 April 1977 Accepted: 27 June 1977 Published: 01 December 1977
Ablation of pulmonary veins works as well as more extensive treatment in persistent atrial fibrillation, study finds
Authors: S. Mayor
Journal: BMJ (2015)

Extensive catheter ablation is no more effective than more targeted ablation to isolate the pulmonary veins in reducing the rate of recurrent atrial fibrillation in patients with persistent atrial fibrillation, a trial reported in the New England Journal of Medicine has found.1

Percutaneous catheter ablation, a minimally invasive procedure in which small areas of cardiac tissue that are firing abnormal electrical impulses are destroyed by heat generated from radio waves, is an effective treatment for paroxysmal atrial fibrillation. Most triggers for the condition come …
Multiple Sclerosis
Authors: Sarah Ringold
Journal: JAMA (2005)

Multiple SclerosisM ultiple sclerosis (MS) is a chronic neurological disorder that affects the central nervous system (brain and spinal cord).The disease process results in inflammation and damage to myelin (insulation for nerve fibers) and other cells within the nervous system.Because myelin aids the conduction of nerve signals, damage to myelin results in impaired nerve signaling and may impair normal sensation, movement, and thinking.This damage occurs in patches that appear as distinct lesions on magnetic resonance imaging (MRI)-the use of magnetic fields to create detailed images of the body.The patches cause different symptoms, depending on their location within the nervous system.Multiple sclerosis primarily affects adults, with an age of onset typically between 20 and 50 years, and is more common in women than in men.The cause of this disorder is not known, but environmental, viral, and genetic factors are thought to play a role.The January 26, 2005, issue of JAMA includes an article reporting that exposure during early childhood to infant brothers and sisters is associated with a reduced risk for MS in later life, possibly due to alterations in immune functions.
An Open Letter to Dr Seed
Authors: Gene Buck
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
Authors: Jorge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiří Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luis Casanova, Brigid Bradley-Garelik, George Manos, Andreas Hochhaus
Journal: Journal of Clinical Oncology (2016)

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib or imatinib. Patients and Methods Patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib 100 mg once daily (n = 259) or imatinib 400 mg once daily (n = 260). Results At the time of study closure, 61% and 63% of dasatinib- and imatinib-treated patients remained on initial therapy, respectively. Cumulative rates of major molecular response and molecular responses with a 4.0- or 4.5-log reduction in BCR-ABL1 transcripts from baseline by 5 years remained statistically significantly higher for dasatinib compared with imatinib. Rates for progression-free and overall survival at 5 years remained high and similar across treatment arms. In patients who achieved BCR-ABL1 ≤ 10% at 3 months (dasatinib, 84%; imatinib, 64%), improvements in progression-free and overall survival and lower rates of transformation to accelerated/blast phase were reported compared with patients with BCR-ABL1 greater than 10% at 3 months. Transformation to accelerated/blast phase occurred in 5% and 7% of patients in the dasatinib and imatinib arms, respectively. Fifteen dasatinib-treated and 19 imatinib-treated patients had BCR-ABL1 mutations identified at discontinuation. There were no new or unexpected adverse events identified in either treatment arm, and pleural effusion was the only drug-related, nonhematologic adverse event reported more frequently with dasatinib (28% v 0.8% with imatinib). First occurrences of pleural effusion were reported with dasatinib, with the highest incidence in year 1. Arterial ischemic events were uncommon in both treatment arms. Conclusion These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP.
Management of Cirrhosis and Ascites
Authors: M Emmanuel Bhaskar
Journal: New England Journal of Medicine (2004)

300 n engl j med 351;3 www.nejm.org july 15, 2004 I agree with Professor Dresser’s view that civility and tolerance are conducive to good policymaking. I would therefore like to reemphasize that my concern about the President’s Council on Bioethics report entitled “Monitoring Stem Cell Research” is that, despite my efforts to have the most recent and most complete input from scientific experts included in the scientific descriptions in the report, these efforts were only partially followed up in the preparation of this report. As a result, coverage of key scientific knowledge in this rapidly moving scientific field was incomplete and hence its scientific content was imbalanced. Elizabeth H. Blackburn, Ph.D. University of California, San Francisco San Francisco, CA 94143-2200 telomer@itsa.ucsf.edu
Biodistribution of 18F-FDG-Labeled Autologous Bone Marrow–Derived Stem Cells in Patients With Type 2 Diabetes Mellitus
Authors: Vikas Sood, Bhagwant R. Mittal, Anil Bhansali, Baljinder Singh, Niranjan Khandelwal, Neelam Marwaha, Ashish Jain
Journal: Clinical Nuclear Medicine (2015)

The study aims to carry out in vivo tracking of stem cells labeled with positron emission tomography (PET) tracer fluorine 18-fluorodeoxyglucose (F-FDG) and find adequate administration methods for these cells in diabetic patients.Bone marrow aspirate was taken from the iliac crest of patients. Bone marrow mononuclear cells were separated and purified using centrifugation. These cells were then labeled with PET tracer F-FDG. The labeled stem cells were given in a total of 21 type 2 diabetes mellitus patients comprising 3 groups of 7 patients each. Cells were infused either in peripheral intravenous route or through the targeted routes into the superior pancreaticoduodenal artery and the splenic artery respectively. Biodistribution and quantification studies were carried out at 30 and 90 minutes of stem cell infusion.Our results show that targeted approach resulted in homing and retention of stem cells in pancreas as compared with the intravenous route where no discernible homing of stem cells was there. Outside the pancreas, liver and spleen showed intense FDG labeled stem cell accumulation. In the intravenous group, lung fields showed retention of cells in the initial biodistribution study at 30 minutes with significant clearance in the delayed 90 minute image.Infusion into the superior pancreaticoduodenal artery should be a preferred route than into the splenic artery as the former method resulted in better homing and retention of labeled stem cells. Homing is least likely to occur when the intravenous route is used.
Bisphosphonates and Tumor Burden
Authors: Gregory R. Mundy
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.15.3191 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12149289 Bisphosphonates and Tumor Burden Gregory R. MundyxGregory R. MundySearch for articles by this author Show More Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX https://doi.org/10.1200/JCO.2002.20.15.3191 Full Text PDF Figures and Tables "Bisphosphonates and Tumor Burden." Journal of Clinical Oncology, 20(15), pp. 3191–3192© 2002 by American Society of Clinical Oncology
Neurochemical variables in delusional depression
Authors: E Lykouras, M Markianos, D Malliaras, C Stefanis
Journal: American Journal of Psychiatry (1988)

The authors assayed plasma dopamine beta-hydroxylase activity, platelet monoamine oxidase (MAO) activity, plasma prolactin, the urinary monoamine metabolites 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA), and urinary cAMP from 18 delusional and 22 nondelusional depressed inpatients. No significant differences between the two groups were found.
Thromboembolic risk of tamoxifen in patients with stage II breast cancer.
Authors: M Levine
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.10.1579 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2610746 Thromboembolic risk of tamoxifen in patients with stage II breast cancer. M LevinexM LevineSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.10.1579 PDF "Thromboembolic risk of tamoxifen in patients with stage II breast cancer.." Journal of Clinical Oncology, 7(10), pp. 1579–1580© 1989 by American Society of Clinical Oncology
Insomnia
Authors: Philip A. Masters
Journal: Annals of Internal Medicine (2014)

This issue provides a clinical overview of Insomnia focusing on prevention, diagnosis, treatment, practice improvement, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of science writers and physician writers. Editorial consultants from ACP Smart Medicine and MKSAP provide expert review of the content. Readers who are interested in these primary resources for more detail can consult http://smartmedicine.acponline.org, http://mksap.acponline.org, and other resources referenced in each issue of In the Clinic.
QOL-10THE MAKING OF ‘GOINGS-ON' - A QUALITY OF LIFE MONITOR APP FOR CANCER PATIENTS AND FAMILIES
Authors: Petra Hoogendoorn
Journal: Neuro-Oncology (2015)

BACKGROUND: My late husband, father of our 3 children of then 8, 6 and 2 years old, was diagnosed with a bi-frontal glioma in 2009. His prognosis was 2 to 20 years with behavioral and cognitive problems. He died in 2012 after in his own words a good life of still 40 years old. In an effort to minimize the effect of the tumor on our family I've initiated the ‘ReMind’ app. ReMind is based on Dr. Karin Gehring's SNO quality of life awarded cognitive rehabilitation research, that was no longer available. The app and game are tested later this year both in the US and the Netherlands. I'm now working on quality of life monitor app ‘Goings-On’ for cancer patients with most probably a fatal diagnosis and their families. The concept has won the Achmea Open Health Community Award. Goings-On helps determine and monitor patient and family goals and functioning. Physician, patient and family can select their own specific items to monitor either via quantified self, photo's or easy scales to better determine if cancer - and palliative treatments are desirable and effective. METHOD: As part of my PhD research in medical decision making I've attended several consultations with oncologists and other cancer related physicians inside and outside of the Netherlands, used available literature and input and feedback from physicians, other medical staff and patient advocates both at and outside the Society for Neuro Oncology Annual Meeting to determine the concept, draft screens and now a clickable prototype. RESULTS: The clickable prototype and reasoning behind design choices will be presented. CONCLUSION: The clickable prototype combined with feedback is to result in a Dutch and English version of Goings-On that can be tested in a randomized controlled trial for effects on treatment choices, health outcomes, quality of life and efficiency.
Control off Some Cell-Contact Reactions in Tissue Culture&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: A. S. G. Curtis
Journal: JNCI Journal of the National Cancer Institute (1961)

The degree of contact inhibition, a contact property shown by normal but not by tumor cells, produced in chick-heart fibroblasts from 9-day-old embryos grown in a liquid medium of serum, embryo extract, and saline, decreases with increasing embryo-extract concentration and with increasing age of the culture. Contact inhibition is controlled in part by the nature of the culture medium, but its display is not directly dependent on the speed of movement of the cell, though it is suggested that both may have a common controlling mechanism. It is not related directly to the incidence of mitosis past or present, but depends partly on the density of cell population.
The Business Side of Medical Practice
Authors: G MARKS
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract A03: A brain cancer cell migration simulator based on a motor-clutch model
Authors: Benjamin L. Bangasser, Steven R. Rosenfeld, David J. Odde
Journal: Cancer Research (2015)

Abstract WHO Grade IV astrocytoma, also known as glioblastoma, is an invasive disease where cell migration drives dispersion of tumor cells throughout the brain. To predict cell migration speeds in complex mechanochemical environments, we developed a cell migration simulator based on our published motor-clutch framework [1-3]. One of the key predictions of our previous modeling is that cell traction force is biphasic with respect to environmental stiffness, i.e. there is an optimal stiffness at which cell traction force is maximal. To test whether such optimality exists within a whole cell migration simulator, we extended our model to allow for multiple cellular protrusions in 1D, 2D, or 3D environments. The cell migration simulator imposes that forces balance and that masses of key elements- actin, adhesions, and myosin motors- are conserved. Using the Gillespie stochastic simulation algorithm implemented in matlab, we simulated cell traction force, F-actin retrograde flow, cell aspect ratio, and cell migration as a function of cell stiffness. We found that all four variables depends biphasically on simulated environmental stiffness with approximately overlapping optima. In addition, the model predicts that the optimal stiffness can be shifted by coordinate shifting of motor and adhesive clutch numbers, a prediction that we are now testing experimentally in vitro. Overall, our modeling results predict that effective anti-migratory treatment of patients will require knowledge of the cell migration speed landscape within parameter space. In particular, we predict that simultaneously inhibiting motors and clutches will be beneficial for patients whose tumors operate near the optimum, largely ineffective for those below the optimum, and potentially detrimental to those above the optimum. Thus, our cell migration simulator provides dynamic physical biomarkers that can potentially be used to classify glioblastoma patients for more precise treatment. References: 1. Bangasser, B.L. and D.J. Odde, Master Equation-Based Analysis of a Motor-Clutch Model for Cell Traction Force. Cellular and Molecular Bioengineering, 2013. 6: p. 449-459. 2. Bangasser, B.L., S.S. Rosenfeld, and D.J. Odde, Determinants of maximal force transmission in a motor-clutch model of cell traction in a compliant microenvironment. Biophys J, 2013. 105(3): p. 581-92. 3. Chan, C.E. and D.J. Odde, Traction dynamics of filopodia on compliant substrates. Science, 2008. 322(5908): p. 1687-91. Citation Format: Benjamin L. Bangasser, Steven R. Rosenfeld, David J. Odde. A brain cancer cell migration simulator based on a motor-clutch model. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr A03.
Concordance between patients and informants on the personality disorder examination
Authors: L P Riso, D N Klein, R L Anderson, P C Ouimette, H Lizardi
Journal: American Journal of Psychiatry (1994)

Difficulties in the assessment of personality disorders and the burgeoning interest in axis II have led to increased use of informants when studying these conditions. The present study sought to evaluate the correspondence between patients and their informants on symptoms of personality disorders.A total of 105 outpatients and knowledgeable informants were independently interviewed by using the Personality Disorder Examination, a widely used instrument for the full range of personality disorders.Diagnostic concordance between interviews was low (median kappa = -0.01), while correlations between dimensional scores were somewhat higher (median kappa = 0.36). Overall, patient interviews showed more pathology than interviews with informants. However, many of the symptoms obtained from informants were not reported by patients.These data suggest that patient-informant concordance for axis II disorders is poor for diagnoses but somewhat better for dimensional scores. There was no evidence that low agreement can be explained by patients attempting to present themselves in a favorable light. Further work is necessary to elucidate the reasons for discordance and determine which data source provides the most valid information.